10-QPeriod: Q2 FY2002

CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 29, 2002

Filed August 9, 2002For Securities:CVS

Summary

CVS Health Corporation reported its second-quarter and year-to-date results for the period ending June 29, 2002. While net sales showed growth, increasing by 9.0% for the quarter and 9.9% year-to-date, net earnings and operating profit declined compared to the prior year. This decline was attributed to a lower gross margin rate, influenced by a shift towards third-party pharmacy sales and increased promotional activity, as well as higher operating expenses. Despite these challenges, the company saw improvements in operating cash flow driven by better working capital management and continued to invest heavily in property and equipment for store development and relocations. The company also implemented an Action Plan in late 2001, which involved store and facility closures and workforce reductions, with a significant restructuring charge recorded in Q4 2001. As of the reporting period, the remaining liability from this charge was $214.3 million. Looking ahead, CVS Health remains focused on its growth strategy, including opening new stores and relocating existing ones to more convenient freestanding locations. The company's liquidity is considered sufficient, supported by operating cash flow and available credit facilities. Investors should note the impact of generic drug introductions and potential future reductions in pharmacy reimbursement rates for governmental programs as key factors influencing future profitability.

Key Highlights

  • 1Net sales increased by 9.0% to $5.99 billion for the quarter and 9.9% to $11.96 billion year-to-date, driven by pharmacy and front store sales growth.
  • 2Net earnings for the quarter decreased by 10.9% to $176.4 million, and year-to-date net earnings fell by 16.1% to $352.1 million, compared to the same periods in 2001.
  • 3Operating profit declined significantly, down 12.8% for the quarter to $298.3 million and 17.8% year-to-date to $594.8 million, reflecting lower gross margins and increased operating expenses.
  • 4Gross margin rate declined due to a higher proportion of lower-margin third-party pharmacy sales and increased promotional markdowns, partially offset by generic drug sales.
  • 5Net cash provided by operating activities improved significantly, increasing to $348.3 million year-to-date from $127.0 million in the prior year, largely due to better working capital management.
  • 6Capital expenditures increased substantially, with $590.3 million spent on property and equipment year-to-date, primarily for new store openings and relocations as part of the company's real estate development program.
  • 7The company continues to manage liabilities from the 2001 Action Plan, with $214.3 million remaining primarily for noncancelable lease obligations as of June 29, 2002.

Frequently Asked Questions

CVS Health's revenue growth is primarily driven by its pharmacy segment, which benefits from an aging population and increased pharmaceutical use. However, profitability is being pressured by a declining gross margin rate. This is due to a growing mix of lower-margin third-party pharmacy sales and increased promotional activities. Additionally, operating expenses have risen, impacting overall operating profit.

The company implemented an 'Action Plan' in late 2001 that involved closing 229 stores, a distribution center, and a mail-order facility, along with workforce reductions. This resulted in a significant restructuring charge in the fourth quarter of 2001. While the store closures impacted total sales growth, the plan is intended to streamline operations and improve efficiency. As of June 29, 2002, $214.3 million in liabilities remained, primarily related to lease obligations from these closures.

CVS Health's liquidity appears strong, with $333.3 million in cash and cash equivalents as of June 29, 2002. The company primarily funds its operations and growth through cash flow from operations, commercial paper, and long-term borrowings. It maintains significant credit facilities to support its liquidity needs. The company expects its cash on hand, operating cash flow, and financing abilities to be sufficient for its near-term and long-term needs.

The company highlights several risks, including intense competition, changes in consumer spending and preferences, potential price reductions, the success of cost-saving initiatives from the Action Plan, litigation, interest rate fluctuations, and regulatory changes. Specifically concerning the pharmacy business, risks include the continued introduction of generic drugs, efforts by third-party payors to reduce drug costs, and potential reductions in pharmacy reimbursement rates for governmental programs like Medicaid.